Cellectis (CLLS) Says Two Issued US Patents Granted for CRISPR Use in T-Cells – StreetInsider.com
Channel NewsAsia |
Cellectis (CLLS) Says Two Issued US Patents Granted for CRISPR Use in T-Cells
StreetInsider.com Cellectis (NASDAQ: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the issuance of two U.S. patents – US 9,855,297 and US 9,890,393 – for the … France's Cellectis wins US patents for gene editing technology |
